Differences of HER2 Status by HercepTest and PATHWAY 4B5 Immunohistochemical Assays in Breast Cancer
HER2 staining was lower in 4B5 testing than in the HercepTest. Companion diagnosis using 4B5 is required to determine indications for T-DXd, especially for HER2-ultralow evaluations.
Authors
- Ai Amioka (ORCID: https://orcid.org/0000-0002-9507-6651)
- Morihito Okada (ORCID: https://orcid.org/0000-0001-7068-6608)
- S. Sasada
- Kanako Suzuki (ORCID: https://orcid.org/0000-0002-9199-0104)
- Mutsumi Fujimoto (ORCID: https://orcid.org/0000-0002-5081-2854)
- Momoko Takaya
- Koji Arihiro
- HARUKA IKEJIRI
Institutions
- Hiroshima University (JP)
- Hiroshima University Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18015
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00